NASDAQ$JANX
Janux Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Janux Therapeutics reported Q1 2026 collaboration revenue of $3.7M and a net loss of $24.4M ($0.39 per share).
Q1 2026 collaboration revenue was $3.7 million from the new BMS agreement versus zero a year ago. Operating expenses were $37.9 million; net loss was $24.4 million ($0.39 per share) versus $23.5 million. Interest income of $9.9 million partially offset R&D spend of $26.8 million.
- Collaboration revenue $3.7M from BMS deal.
- Net loss $(24.4)M; EPS $(0.39).
- R&D $26.8M on T-cell engager platform.
- Interest income $9.9M on cash balance.
- Deferred revenue $46.3M under BMS agreement.
Headline financials
Revenue & EPS history
Janux · Revenue · Quarterly
$3.73M
Revenue by segment
Janux · $1.06M total across 1 segment · Q2 2023
- Collaboration revenue$1.06M-55.3%100.0%
Forward guidance
Filings highlight BMS collaboration milestones, Merck partnership completion, and clinical catalysts rather than EPS guidance.
Tailwinds
- New BMS revenue stream and deferred revenue build.
- Strong interest income on raised capital.
Headwinds
- Rising R&D on pipeline expansion.
- Still pre-product with ongoing losses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.6%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-5.5%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-11.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -1.4% | -8.8% | |
| Q4 2025 | -1.4% | +4.0% | -4.5% | |
| Q3 2025 | +3.9% | +4.8% | -40.1% | |
| Q1 2025 | -0.8% | +3.8% | -2.8% | |
| Q4 2024 | +2.7% | -1.6% | -9.1% | |
| Q3 2024 | -1.9% | -2.9% | +17.6% | |
| Q2 2024 | -1.1% | -0.8% | +11.8% | |
| Q1 2024 | -11.0% | -21.3% | -31.5% | |
| Q4 2023 | -1.6% | -1.7% | -13.5% | |
| Q3 2023 | +5.9% | -3.4% | +50.7% | |
| Q2 2023 | +5.1% | +4.3% | -11.6% | |
| Q1 2023 | +1.1% | -7.0% | -3.5% | |
| Q4 2022 | -2.5% | -4.7% | -4.9% | |
| Q3 2022 | +14.6% | +5.3% | -9.8% | |
| Q2 2022 | +1.0% | -4.9% | -3.2% | |
| Q1 2022 | +6.1% | +13.7% | +10.0% | |
| Q4 2021 | -6.0% | -3.5% | -17.1% | |
| Q3 2021 | -1.6% | -7.4% | -23.9% | |
| Q2 2021 | -1.0% | -3.8% | -9.9% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro